Is Cardiology’s Biggest Reversal Coming?
When it came time to write about the CLOSURE-AF trial of percutaneous left atrial appendage closure (LAAC) vs…
Rivaroxaban or Combo Therapy: A Winner for All Ages? – Medscape
Rivaroxaban or Combo Therapy: A Winner for All Ages? Medscape Rivaroxaban Monotherapy Benefits Those with Atrial Fibrillation, Stable Coronary…
PCPs Guide to Prescribing Blood Thinners for AF
As a primary care physician (PCP), you’re often the first healthcare professional that will identify cardiac issues, including…
Your Patient’s Smartwatch Could Be a Legal Time Bomb
A few years ago, a patient in her 30s saw Nicholas Dragolea, MBBS, a general practitioner when her…
Anticoagulants in AF Post-ICH: The Dilemma Continues
TOPLINE: In patients with atrial fibrillation (AF) with a recent episode of intracranial hemorrhage (ICH), the use of…
Can Cardiology’s Oldest Drug Make a Comeback?
Cardiac glycosides derived from the foxglove plant have been used in cardiology for two centuries, but digoxin and…
Genetic Tests in AF Patients May Flag Heart Failure Risk
Genetic testing in patients with atrial fibrillation (AF) may identify those at higher risk of developing incident cardiomyopathy…
Anticoagulation in Subclinical AF May Offer Little Benefit
TOPLINE: In a modeling analysis, initiating direct acting or nonvitamin K oral anticoagulants (DOAC/NOAC) in patients with device-detected…